Search filters

List of works by Susana Banerjee

#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

scientific article published on 12 December 2019

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG ⬇️

scientific article published on October 5, 2012

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

scientific article published on 10 July 2014

Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

scientific article published on 27 October 2021

Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?

scientific article published on May 2014

Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data

scientific article published on 31 March 2020

An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancer

scientific article published on 01 November 2020

Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer

scientific article published on 21 October 2019

Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International Survey

scientific article published on 06 December 2019

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

scientific article

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

scientific article published on 10 April 2017

Becoming a new consultant: how to make it work for you

scientific article published on 01 February 2010

Bevacizumab in cervical cancer: a step forward for survival

scientific article published on 27 July 2017

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer.

scientific article

Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo

scientific article published on 3 August 2010

Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor

scientific article

Burnout in oncologists is a serious issue: What can we do about it?

scientific article published on 16 May 2018

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

scientific article

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

scientific article

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial

scientific article published on 01 October 2020

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

scientific article

Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?

scientific article published on 01 October 2020

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients

scientific article published on 4 November 2016

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

scientific article published on 13 December 2016

Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE)

scientific article published on 17 June 2020

Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker

scientific article published on 01 October 2019

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

scientific article published in June 2022

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

scientific article published on 29 September 2008

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

scientific article (publication date: 2016)

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

scientific article published on 09 January 2019

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial

scientific article published on 04 August 2020

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

scientific article published on 06 August 2013

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer ⬇️

scientific article published on August 2, 2012

Exploiting the folate receptor α in oncology

scientific article published on 09 March 2020

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

scientific article published on 9 February 2018

First-line PARP inhibition in ovarian cancer - standard of care for all?

scientific article published on 01 March 2020

First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion

scientific article published on 01 November 2020

From Burnout to Resilience: An Update for Oncologists

scientific article published on 01 May 2018

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

scientific article published on 7 October 2024

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey

scientific article published on 21 September 2018

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

scientific article published on 17 December 2018

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

scientific article

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients

scientific article published in June 2017

Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

scientific article published on 28 February 2012

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

scientific article

Imaging in the pre-operative staging of ovarian cancer

scientific article published on 01 February 2019

Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians

scientific article published on 01 December 2020

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

scientific article published on 13 July 2016

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer

scientific article published on 19 December 2012

Improving outcomes for older women with gynaecological malignancies

scientific article published on 29 August 2016

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

scientific article

Let's address burnout in oncologists and reimagine the way we work

scientific article published on 01 January 2019

Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR

scientific article published on 20 November 2019

Low-grade serous ovarian cancer: expert consensus report on the state of the science

scientific article published on 17 August 2023

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

scientific article published on 21 August 2020

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

article

Making the best of PARP inhibitors in ovarian cancer

scientific article published on 10 August 2010

Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review

scientific article

Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives

scientific article published on 12 August 2019

Management of melanomas of the gynaecological tract

scientific article

Management of small HER2-positive breast cancers

scientific article published on December 2010

Mechanisms of disease: angiogenesis and the management of breast cancer

scientific article published on September 2007

Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity

scientific article published in Nature Communications

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

scientific article published on 15 August 2023

Molecular targets and targeted therapeutics in endometrial cancer

scientific article published on September 2012

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential

scientific article published on 10 January 2013

Nintedanib in ovarian cancer.

scientific article published on 19 July 2017

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

scientific article published on 16 September 2019

Olaparib and somatic BRCA mutations

scientific article published on 8 June 2017

Olaparib for the treatment of epithelial ovarian cancer

scientific article published on 11 March 2016

Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation

scientific article published on 24 August 2018

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

scientific article

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.

scientific article published on 16 April 2018

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

scientific article published on 13 August 2020

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond

scientific article

PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper

article by Gabor Liposits et al published 14 October 2018 in Journal of Geriatric Oncology

PARP inhibitors in ovarian cancer: an overview of the practice-changing trials

scientific article published on 31 December 2020

PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

scientific article published on 24 August 2020

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial

scientific article published on 10 January 2020

Pazopanib in ovarian cancer

scientific article published on 21 August 2015

Personalized therapy in gynecological cancer: a reality in clinical practice?

scientific article published in June 2013

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer

scientific article published on 14 February 2018

Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).

scientific article published on 26 August 2015

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer

scientific article

Progression-free survival versus overall survival in ovarian cancer: where are we now?

scientific article published on 01 December 2012

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

scientific article published on 17 July 2018

Quantitative histology analysis of the ovarian tumour microenvironment.

scientific article

Recent advances in systemic treatments for ovarian cancer

scientific article

Reply to 'Physician burnout: let's avoid unsubstantiated claims'

scientific article published on 01 February 2019

Report on the status of women occupying leadership roles in oncology

scientific article published on 21 September 2018

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

scientific article published on 09 December 2019

Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma

scientific article published on 22 January 2014

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

scientific article published on 01 May 2020

Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines

scientific article published on 10 March 2020

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Targeted agents and combinations in ovarian cancer: where are we now?

scientific article published on 4 March 2016

Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.

scientific article published on June 2010

Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary

scientific article published on 29 July 2016

The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer ⬇️

scientific article published on 01 April 2011

The current state of pemetrexed in ovarian cancer

scientific article published on 31 July 2013

The current status of PARP inhibitors in ovarian cancer

scientific article published on 24 September 2016

The current status of immunotherapy for cervical cancer

scientific article published on 18 May 2018

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

scientific article published on 31 July 2020

The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer

scientific article published in May 2008

The follow-up of women at high risk for breast cancer relapse

scientific article published on 01 October 2009

The future of targeted therapies in ovarian cancer

scientific article published on 10 July 2009

The integration of BRCA testing into oncology clinics

scientific article published on June 2016

The role of Cediranib in ovarian cancer

scientific article published on 21 September 2017

The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole

scientific article

The role of targeted therapy in ovarian cancer

scientific article published on September 2011

The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase

scientific article published on 12 May 2009

Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers

scientific article published on 13 September 2011

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

scientific article published in February 2022

Translational genomics of ovarian clear cell carcinoma

scientific article published on 04 November 2019

Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases

scientific article published on 22 November 2015

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

scientific article published on 29 November 2019

Paulina is supported by:

About Paulina

Help